Last reviewed · How we verify
TAA-specific CTLs- fixed dose
At a glance
| Generic name | TAA-specific CTLs- fixed dose |
|---|---|
| Sponsor | Baylor College of Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma (PHASE1)
- TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer (PHASE2)
- Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAA-specific CTLs- fixed dose CI brief — competitive landscape report
- TAA-specific CTLs- fixed dose updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI